Recnac Oncology Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 94.75%
- Profit Growth 321.58%
- Ebitda 480.08%
- Net Worth 62.15%
- Total Assets 111.61%
About Recnac Oncology
Recnac Oncology Private Limited (ROPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 November 2018 (Six years and three months 4 days old ). Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Dhanasekar Padmanabhan, Duraisamy Sriprakash, Ramani Balaji, and Two other members serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U93000TN2018PTC125864
- Company No.
125864
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Nov 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Recnac Oncology?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Duraisamy Sriprakash  | Managing Director | 19-Nov-2018 | Current |
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ganesamoni Sivaram | Additional Director | 23-Nov-2018 | Current |
| Ramani Balaji | Director | 19-Nov-2018 | Current |
| Dhanasekar Padmanabhan | Director | 19-Nov-2018 | Current |
| Mahalingam Sivakumar | Additional Director | 23-Nov-2018 | Current |
Financial Performance of Recnac Oncology.
Recnac Oncology Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 94.75% increase. The company also saw a substantial improvement in profitability, with a 321.58% increase in profit. The company's net worth Soared by an impressive increase of 62.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Recnac Oncology?
In 2021, Recnac Oncology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bavida Ventures LlpDhanasekar Padmanabhan is a mutual person
- Vinayaggas Infratech Private Limited
Ganesamoni Sivaram is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Recnac Oncology?
Unlock and access historical data on people associated with Recnac Oncology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Recnac Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Recnac Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.